President Trump recently announced agreements with Eli Lilly and Novo Nordisk. These deals aim to slash prices for popular obesity drugs. As a result, millions of Americans gain better access to treatments like Ozempic and Wegovy.
Consider the drugs involved. Novo Nordisk produces Ozempic and Wegovy. Eli Lilly makes Mounjaro and Zepbound. These medications help with weight loss and related conditions.
Key Price Reductions Unveiled
The deals set Medicare prices at $245 per month for these drugs. This amount falls below half of previous proposals. Consequently patients save significantly on costs.
In addition, out of pocket expenses drop. Medicare users pay a $50 copay. Starting doses of upcoming oral pills cost $149 monthly. These changes start mid-2026 for Medicare coverage.
Moreover Trump Rx offers direct access. Prices through this program begin at $350 and reduce to $245 over two years. Self pay options for Zepbound pens range from $299 to $449.
Expanding Access and Investment
The agreements expand coverage. Medicare now includes obesity treatments for eligible patients. This affects about 10% of enrollees with conditions like heart disease.
Furthermore companies commit to investments. Novo Nordisk pledges $10 billion in U.S. manufacturing. Eli Lilly invests $27 billion. These moves support domestic production.
Reactions and Future Outlook
Stakeholders react mixedly. Experts praise lower prices but note challenges. For instance, implementation details remain unclear. Nevertheless the deals promise relief for many.
This initiative tackles high drug costs. It promotes health equity and economic benefits. Society watches as these changes unfold.
